Table 1 Potentially inappropriate medications (PIMs) prescribed during the 90-day follow-up period (N = 17,912)
Types of potentially inappropriate medications | Potentially inappropriate medications |
|---|---|
Number of patients (% of total number of patients with PIM prescription) | |
All | 447 (2.5% of patients in cohort) |
Anticholinergics | 64 (14.3) |
 First-generation antihistamines | 52 (11.6) |
 Antiparkinsonian agents | ** |
 Antispasmodics | ** |
Anti-infective (Nitrofurantoin) | ** |
Cardiovascular | 90 (20.1) |
 Peripheral alpha-1 blockers | 14 (3.1) |
 Central alpha agonists | ** |
 Disopyramide | ** |
 Digoxin | 57 (12.8) |
 Nifedipine | ** |
 Amiodarone | 21 (4.7) |
Central nervous system | 185 (41.4) |
 Antidepressants | ** |
 Antipsychotics | 35 (7.8) |
 Barbiturates | ** |
 Benzodiazepines | 130 (29.1) |
 Nonbenzodiazepine | 29 (6.5) |
Endocrine | 77 (17.2) |
 Androgens | ** |
 Growth hormone | 16 (3.6) |
 Insulin | 39 (8.7) |
 Megestrol | ** |
 Sulfonylureas | 16 (3.6) |
Gastrointestinal | 20 (4.5) |
 Metoclopramide | 12 (2.7) |
 Mineral oil | ** |
 Proton-pump inhibitors | ** |
Pain medications | 54 (12.1) |
 Non-cycloocygenase-selective NSAIDs | 17 (3.8) |
 Indomethacin, ketorolac | 20 (4.5) |
 Skeletal muscle relaxants | 18 (4.0) |